Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1299-1313
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1299
Table 1 Baseline characteristics of the study population

All (n = 43)
Control (n = 21)
Intervention (n = 22)
P value
Sex n (%) F/M26 (60.5)/17 (39.5)12 (46.2)/9 (52.9)14 (53.8)/8 (47.1)0.663
Age (yr)53.5 ± 7.853.7 ± 8.253 ± 7.60.768
BMI (kg/m2)29.5 ± 4.229.2 ± 3.729.8 ± 4.80.635
Etiology of cirrhosis
HCV n (%)14 (32.6)6 (28.5)8 (36.4)0.063
AIH n (%)9 (20.9)3 (14.3)6 (27.3)
NAFLD n (%)8 (18.6)5 (23.8)3 (13.6)
Others1 n (%)12 (27.9)7 (33.4)5 (22.7)
History of complications [n (%)]
Variceal bleeding 2 (4.7)2 (9.5)0 (0)0.233
Encephalopathy 1 (2.3)0 (0)1 (4.5)0.500
Ascites 5 (11.6)3 (14.3)2 (9.1)0.664
Child-Pugh stage
A 38 (88.4)20 (95.2)18 (81.9)0.345
B 5 (11.6)1 (4.8)4 (18.1)
Child-Pugh5 (5-6)5 (5-6)5 (5-6)0.617
MELD score8 (7-10)8 (7.5-9.5)8.5 (7-10)0.524
Biochemical parameters
TB (mg/dL)1.19 (0.82-1.95)1.15 (0.75-1.44)1.28 (0.85-2.11)0.284
ALT (U/L)43 (26-77)43 (30-86.5)43.1 (20.75-77)0.882
AST (U/L)48 (37-93)47 (40-80)50.5 (32-98)0.881
AP (mg/dL)142.2 ± 57.7123.7 ± 44.1159.8 ± 64.40.039
Albumin (g/dL) 4.0 (3.6-4.2)4.1 (3.8-4.3)3.9 (3.3-4.1)0.170
Leukocytes (K/µL)4.2 (3.7-5.3)4.0 (3.7-5.15)4.75 (3.725-5.925)0.233
Platelets (K/µL)80 (62-125)77 (61.5-125)93.5 (63.5-125)0.520
Hemoglobin (g/dL)14.1 ± 1.9414.2 ± 3.314.0 ± 2.40.755
INR1.1 (1.1-1.2)1.1 (1.1-1.2)1.1 (1.1-1.2)0.870
Glucose (mg/dL) 91 (83-103)94 (83.5-109)91 (81-100.5)0.882
Creatinine (mg/dL) 0.72 (0.63-0.80)0.72 (0.60-0.81)0.71 (0.64-0.79)0.892
Sodium (mmol/L) 139 (137-141)140 (137.5-141)138 (137-140.2)0.290
Potassium (mmol/L)4.08 ± 0.324.0 ± 0.374.1 ± 0.250.198
CO2 (mmol/L)24 (21-26)23.0 (21.5-26)24.5 (21-27.25)0.518

  • Citation: Macías-Rodríguez RU, Ruiz-Margáin A, Román-Calleja BM, Espin-Nasser ME, Flores-García NC, Torre A, Galicia-Hernández G, Rios-Torres SL, Fernández-del-Rivero G, Orea-Tejeda A, Lozano-Cruz OA. Effect of non-alcoholic beer, diet and exercise on endothelial function, nutrition and quality of life in patients with cirrhosis. World J Hepatol 2020; 12(12): 1299-1313
  • URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1299.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1299